Sanofi Q3 sales rise 16.2% to €14.44 billion

Sanofi (NASDAQ:SNY) reported third-quarter 2026 net sales of €14.44 billion, up 16.2% year over year, as business earnings per share increased 22% to €3.55.

The results exceeded analyst expectations, with net sales surpassing the approximately €13.25 billion consensus and business EPS beating the €2.79 estimate, while revenue growth reached 14.3% at constant exchange rates.

IFRS net income increased 7.8% to €3.021 billion, while business net income rose 20% to €4.255 billion, with Dupixent sales climbing 34.8% to €5.7 billion and new pharmaceutical launches increasing 31.4% to €1.4 billion.

Vaccine sales declined 6.6% to €3.2 billion, while Sanofi raised its 2026 sales growth forecast to a low-teens percentage and its business EPS growth forecast to a mid-teens percentage, both at constant exchange rates.

Management also highlighted an expanded alliance with Regeneron and a portfolio partnership with Cheplapharm, while identifying business development and acquisitions as important parts of its strategy beyond Dupixent's expected loss of exclusivity.

Sanofi's broader strategy includes expanding its pharmaceutical launches, strengthening its immunology and rare disease businesses, improving research and development productivity and preparing its product portfolio for the period following Dupixent's loss of exclusivity.